What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non-Small Cell Lung Cancer...

Area of Science:

• Oncology
• Immunotherapy
• Genomics

Background:

• Non-small cell lung cancer (NSCLC) is a leading cause of cancer mortality globally.
• While targeted therapies and immunotherapies have improved outcomes, many patients, particularly those without actionable genomic alterations (AGAs), face disease progression.
• Limited second-line and beyond treatment options exist for advanced NSCLC patients without AGAs.

Purpose of the Study:

• To review current treatment strategies, emerging therapies, challenges, and unmet needs for advanced NSCLC patients without AGAs.
• To highlight novel therapeutic approaches and future directions in managing this patient population.

Main Methods:

• Literature review of pivotal clinical trials and emerging research.
• Analysis of treatment outcomes for standard and investigational therapies.
• Discussion of challenges in treatment selection and resistance mechanisms.

Main Results:

• Docetaxel with or without ramucirumab is the standard second-line therapy post-platinum chemotherapy and immunotherapy.
• Targeted therapy is restricted to patients with specific AGAs.
• Bispecific antibodies, like ivonescimab, demonstrate early encouraging efficacy.
• AI-driven radiomics and pathomics may aid future treatment selection.
• Antiangiogenic agents combined with immune checkpoint inhibitors (ICIs) show mixed results post-progression.

Conclusions:

• Patients with advanced NSCLC without AGAs progressing after chemoimmunotherapy have limited therapeutic choices.
• Novel agents, including bispecific antibodies, offer potential new avenues.
• Development of predictive biomarkers and understanding ICI resistance mechanisms are critical for future treatment advancements.